EGFR and K-ras mutations in cytologic samples from fine-needle aspirates in NSCLC patients

摘要

Mutations in the epidermal growth factor receptor (EGFR) gene in patients with nonsmall cell lung cancer (NSCLC) have been correlated with tumour response to treatment with targeted tyrosine kinase inhibitors (TKIs), especially gefitinib and erlotinib [1, 2]. A large number of studies have reported a significantly higher overall response rate, overall survival and time-to-progression in patients with EGFR-activating mutations compared with those with wild-type tumours [3-5].